Drug Utilization Evaluation of Intravenous Pantoprazole with Focus on Appropriateness, Route Switching, and Economic Impact in a Pediatric Tertiary Hospital
-
Maryam Shahrokhi
,
Shohreh Maleknejad
,
Mahdi Ahmadinia
,
Nazanin Nikkhooy
,
Faezeh Jamali
,
Roja Qobadighadikolaei
Abstract
Background: Proton pump inhibitors (PPIs), including intravenous (IV) pantoprazole, are frequently prescribed in hospital settings. Although effective, IV formulations are often used inappropriately, leading to unnecessary risks and increased financial burden. Data on IV pantoprazole use in pediatric populations remain limited.
Methods: This study was designed as a retrospective, descriptive, cross-sectional Drug Utilization Evaluation (DUE) conducted in a tertiary pediatric teaching hospital. All inpatients aged ≥3 months who received at least one dose of IV pantoprazole during hospitalization were included. Prescribing appropriateness was evaluated according to international guidelines with respect to indication, dose, route, and duration. Opportunities for intravenous-to-oral (IV-to-PO) conversion and direct medication costs were also assessed.
Results: A total of 260 pediatric patients were analyzed. Overall, 42% of IV pantoprazole prescriptions were classified as appropriate, reflecting the composite appropriateness score across all evaluated domains (indication, dose, route, and duration). The majority of prescribing errors were related to unjustified indications and prolonged duration of therapy. Nearly 81% of eligible patients did not undergo IV-to-PO conversion. Dosing deviations were uncommon. Economic analysis showed that 76.6% of total pantoprazole expenditures were attributable to inappropriate use, corresponding to approximately 1.57 billion Iranian Rials (IRR) [≈8,300 United States dollars (USD)]. The Internal Medicine II ward accounted for the highest absolute excess cost, while the Surgery ward demonstrated 92.3% inappropriate prescribing.
Conclusion: PInappropriate use of IV pantoprazole is prevalent among pediatric inpatients, primarily driven by unjustified indications and missed opportunities for IV-to-PO conversion. These practices impose substantial economic costs and raise safety concerns. Implementation of pharmacist-led DUE and stewardship interventions may improve prescribing practices, reduce unnecessary expenditures, and enhance the quality of pediatric patient care.
Izadi R, Habibolahi A, Jahanmehr N, Khodakarim S. Irrational prescription and its costs in neonatal surfactant therapy: public and private hospitals of Iran in 2018. BMC Pediatr. 2023;23(1):251.
Kim SJ, Han KT, Kang HG, Park EC. Toward safer prescribing: evaluation of a prospective drug utilization review system on inappropriate prescriptions, prescribing patterns, and adverse drug events and related health expenditure in South Korea. Public Health. 2018;163:128–36.
Berthe-Aucejo A, Nguyen PKH, Angoulvant F, Bellettre X, Albaret P, Weil T, et al. Retrospective study of irrational prescribing in French paediatric hospital: prevalence of inappropriate prescription detected by Pediatrics: Omission of Prescription and Inappropriate prescription (POPI) in the emergency unit and in the ambulatory setting. BMJ Open. 2019;9(3):e019186.
Carver N, Jamal Z, Dering Anderson AM. Drug Utilization Review. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2026.
Shahbazi Khamas S, Darvishi F, Taghvaye-Masoumi H, Rafiei E, Jafari A. The Utilization Evaluation of Intravenous Pantoprazole for Stress Ulcer Prophylaxis in a Major Teaching Hospital. J Pharm Care. 2022;10(3):128-135.
Zelalem A, Sisay M, Vipham JL, Abegaz K, Kebede A, Terefe Y. The prevalence and antimicrobial resistance profiles of bacterial isolates from meat and meat products in Ethiopia: a systematic review and meta-analysis. Int J Food Contam. 2019;6(1):1.
Shanika LGT, Reynolds A, Pattison S, Braund R. Proton pump inhibitor use: systematic review of global trends and practices. Eur J Clin Pharmacol. 2023;79(9):1159–72.
Dutta AK, Sharma V, Jain A, Elhence A, Panigrahi MK, Mohta S, et al. Inappropriate use of proton pump inhibitors in clinical practice globally: a systematic review and meta-analysis. Gut. 2025;74(1):e5.
Andrawes M, Andrawes W, Das A, Siau K. Proton Pump Inhibitors (PPIs)—An Evidence-Based Review of Indications, Efficacy, Harms, and Deprescribing. Medicina (B Aires). 2025;61(9):1569.
Targownik LE, Fisher DA, Saini SD. AGA Clinical Practice Update on De-Prescribing of Proton Pump Inhibitors: Expert Review. Gastroenterology. 2022;162(4):1334–42.
Mari A, Marabotto E, Ribolsi M, Zingone F, Barberio B, Savarino V, et al. Encouraging appropriate use of proton pump inhibitors: existing initiatives and proposals for the future. Expert Rev Clin Pharmacol. 2023;16(10):913–23.
Mohzari YA, Alsaegh A, Basheeruddin Asdaq SM, Al Shanawani SN, Albraiki AA, Bagalb A. The Pattern of Intravenous Proton-Pump Inhibitor Utilization at an Academic Medical Center in Riyadh, Saudi Arabia. J Res Pharm Pract. 2020;9(3):151–4.
Bischoff LM, Faraco LSM, Machado LV, Bialecki AVS, Almeida GM de, Becker SCC. Inappropriate usage of intravenous proton pump inhibitors and associated factors in a high complexity hospital in Brazil. Arq Gastroenterol. 2021;58(1):32–8.
Abukhalil AD, Ali O, Saad A, Falana H, Al-Shami N, Naseef HA, et al. Evaluation of Proton Pump Inhibitors Prescribing Among Hospitalized Patients: A Cross-Sectional Study. Int J Gen Med. 2023 11;16:141-150.
Alam S, Qureshi SI, Shakeel A, Javed A, Sami N, Ahmad B. Inappropriate Use of Proton Pump Inhibitors for Stress Ulcer Prophylaxis in a Tertiary Care Hospital: A Cross-Sectional Study. Cureus. 2025;17(4):e83010.
Medscape [Internet]. Pantoprazole (Protonix) dosing, indications, interactions, adverse effects, and more. New York (NY): WebMD LLC; 2021 [cited 2025 Dec 27]. Available from: https://reference.medscape.com/drug/protonix-pantoprazole-342001
IWK Health Centre [Internet]. Pantoprazole – Pediatric Drug Dosing Guidelines. Halifax (NS): IWK Drug Information Resource; 2019 [cited 2025 Dec 27]. Available from: https://www.dir.iwk.nshealth.ca/Home/DDGDetails/cc616e51-9bb3-e911-80f4-005056b200d2?PatientPopulation=Ped
U.S. Food and Drug Administration [Internet]. Protonix I.V. (pantoprazole sodium) for injection, for intravenous use: prescribing information. Silver Spring (MD): FDA; 2024 [cited 2025 Dec 27]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/020988s070lbl.pdf
Drugs.com Editorial Team [Internet]. Pantoprazole dosage guide with precautions. Drugs.com; 2024 [updated 2024 Nov 19; cited 2025 Dec 27]. Available from: https://www.drugs.com/dosage/pantoprazole.html
Taghizadeh-Ghehi M, Mousavi S, Laki B, Kargar M, Javadi MR, Gholami K. Physicians’ Compliance With Order Entry Forms for Intravenous Pantoprazole in a Tertiary Care Hospital. Acta Med Iran. 2023;61(6):361-370.
Khoury N, Stepensky D, Abu Freha N, Mahamid M, Khoury T, Mari A. Predictive Factors Associated with Inappropriate Intravenous Proton Pump Inhibitor Use in Hospitalized Patients: A Case-Control Study. Medicina (B Aires). 2024;61(1):10.
Sutton MM, Gregoski MJ, Rockey DC. Overuse of Intravenous Proton-Pump Inhibitors in the Treatment of Low-Risk Upper Gastrointestinal Bleeding. J Clin Gastroenterol. 2026 1;60(3):268-272.
Akkawi ME, Elnaem MH. Evaluation of the prescribing of proton pump inhibitors as stress ulcer prophylaxis for non-ICU patients in a Malaysian tertiary hospital. Drugs Ther Perspect. 2020;36(11):529–34.
Hong MT, Monye LC, Seifert CF. Acid Suppressive Therapy for Stress Ulcer Prophylaxis in Noncritically Ill Patients. Ann Pharmacother. 2015;49(9):1004–8.
Alosaily YA, Alfallaj JM, Alabduljabbar JS, Alfehaid EF, Alfayez OM, Elrasheed M. Appropriateness of proton pump inhibitors use in noncritically ill hospitalized children in a tertiary hospital in Saudi Arabia. Saudi Pharm J. 2023;31(9):101723.
Bez C, Perrottet N, Zingg T, Leung Ki E, Demartines N, Pannatier A. Stress ulcer prophylaxis in non‐critically ill patients: a prospective evaluation of current practice in a general surgery department. J Eval Clin Pract. 2013;19(2):374–8.
Gandhi S, Taylor B, Rubens L, Gautam N, Sherman N, Chittuluru K, et al. Safety of Intravenous Pantoprazole Sodium in Pediatric Patients Aged 1 Month to < 1 Year: A Real-World Retrospective Cohort Study. Ther Innov Regul Sci. 2024;58(1):166–74.
Dipasquale V, Cicala G, Spina E, Romano C. A Narrative Review on Efficacy and Safety of Proton Pump Inhibitors in Children. Front Pharmacol. 2022 10;13:839972.
Aghdam MM, Servat A, Esmaeili A, Pashaei M. Evaluation of Prescribing Proton Pump Inhibitors among Hospital Inpatients in a Teaching Hospital: Report from Northwest of Iran. Govaresh. 2025;29(4):215–25.
Arnoux A, Bailhache M, Tetard C, Rebouissoux L, Clouzeau H, Lamireau T, et al. Proton pump inhibitors are still overprescribed for hospitalized children. Arch Pédiatrie. 2022;29(4):258–62.
Lassalle M, Zureik M, Dray-Spira R. Proton Pump Inhibitor Use and Risk of Serious Infections in Young Children. JAMA Pediatr. 2023 1;177(10):1028-1038.
Alla D, Shah DJ, Seepana M, Salian RB, Alla SSM, Krishna Mohanan M, et al. Safety of Proton Pump Inhibitors in Pediatric Population: A Systematic Review. Glob Pediatr Health. 2024;11:2333794X241248967.
Ahrens D, Behrens G, Himmel W, Kochen MM, Chenot JF. Appropriateness of proton pump inhibitor recommendations at hospital discharge and continuation in primary care. Int J Clin Pract. 2012;66(8):767–73.
McMullan BJ, Mahony M, Java L, Mostaghim M, Plaister M, Wu C, et al. Improving intravenous-to-oral antibiotic switch in children: a team-based audit and implementation approach. BMJ Open Qual. 2021;10(1):e001120.
Chen Q, Wang Q, Zhang Y. Clinical Intervention Increases Rational Use of Proton Pump Inhibitors in the General Surgery Department. Front Pharmacol. 2022;13:864081.
Iranshahi M, Hassanpour R, Sistanizad M, Malekpour H, Ashnagar A, Pourheidar E. The Effect of the Utilization of a Preprinted Protocol for the Use of Intravenous Pantoprazole on Its Appropriate Administration. J Pharmacoeconomics Pharm Manag. 2022;8(1/2):31–37.
Sami R, Salehi K, Sadegh R, Solgi H, Atashi V. Barriers to rational antibiotic prescription in Iran: a descriptive qualitative study. Antimicrob Resist Infect Control. 2022;11(1):109.
Aiesh BM, Nazzal MA, Abdelhaq AI, Abutaha SA, Zyoud SH, Sabateen A. Impact of an antibiotic stewardship program on antibiotic utilization, bacterial susceptibilities, and cost of antibiotics. Sci Rep. 2023;13(1):5040.
Golfeshan E, Heidari S, Abbasi M, Vahedian M, Dehghani Khorramabadi H, Abdi B, et al. Investigation on the States of Antibiotics Prescription in Hospitals in Qom, Iran, during 2019. Qom Univ Med Sci J. 2020;14(5):12–21.
Khorshidi-Malahmadi I, Sima S, Ansari N, Moghaddas A. Second-year Outcomes of Implementing Antimicrobial Stewardship Program in a Tertiary Pediatric Hospital. Jundishapur J Microbiol. 2021;14(8):e118460.
Meskarpour-Amiri M, Shokri N, Aliyari S, Bahadori M, Hosseini-Shokouh SM. Strategies to reduce costs and increase revenue in hospitals: a mixed methods investigation in Iran. BMC Health Serv Res. 2025;25(1):127.
Sadatsharifi A, Davarpanah MA, Namazi S, Mottaghi S, Mahmoudi L. Economic Burden Of Inappropriate Empiric Antibiotic Therapy: A Report From Southern Iran. Risk Manag Healthc Policy. 2019 12;12:339-348.
Ofori-Asenso R, Brhlikova P, Pollock AM. Prescribing indicators at primary health care centers within the WHO African region: a systematic analysis (1995–2015). BMC Public Health. 2016;16(1):724.
| Files | ||
| Issue | Vol 13, No 4 (Autumn 2025) | |
| Section | Original Article(s) | |
| Keywords | ||
| Intravenous pantoprazole Pediatric inpatients Drug utilization evaluation Proton pump inhibitors Hospital pharmacy services | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
